Revolution Medicines to present Phase 1/2 zoldonrasib-chemo data in first-line KRAS G12D metastatic pancreatic cancer at ESMO GI 2026

Revolution Medicines

Revolution Medicines

RVMD

0.00
  • Revolution Medicines flagged upcoming Phase 1/2 pancreatic cancer readouts for its RAS(ON) inhibitor zoldonrasib in combination regimens.
  • Results will be presented July 2 at the ESMO Gastrointestinal Cancers Congress in Munich, covering first-line chemo combinations and later-line pairing with daraxonrasib.
  • The update points to early evidence of manageable safety and antitumor activity, supporting broader development in RAS G12D metastatic pancreatic cancer.
  • Phase 3 programs also advanced, with trials-in-progress disclosures for RASolute 303 in first-line metastatic disease and RASolute 304 in the adjuvant setting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606241931PRIMZONEFULLFEED9752309) on June 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.